Aim: To investigate the relationship between effective fentanyl sublingual spray (FSS) doses for breakthrough cancer pain (BTCP) and around-the-clock (ATC) transdermal fentanyl patch (TFP). Methods: Adults tolerating ATC opioids received open-label FSS for 26 days, followed by a 26-day double-blind phase for patients achieving an effective dose (100-1600 mu g). Results: Out of 50 patients on ATC TFP at baseline, 32 (64%) achieved an effective dose. FSS effective dose moderately correlated with mean TFP dose (r = 0.4; p = 0.03). Patient satisfaction increased during the study. Common adverse events included nausea (9%) and peripheral edema (9%). Conclusion: FSS can be safely titrated to an effective dose for BTCP in patients receiving ATC TFP as chronic cancer pain medication. ClinicalTrials.gov identifier: NCT00538850
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/621765 |
| Date | 10 1900 |
| Creators | Alberts, David S, Smith, Christina Cognata, Parikh, Neha, Rauck, Richard L |
| Contributors | University of Arizona |
| Publisher | FUTURE MEDICINE LTD |
| Source Sets | University of Arizona |
| Language | English |
| Detected Language | English |
| Type | Article |
| Rights | This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/ |
| Relation | http://www.futuremedicine.com/doi/10.2217/pmt-2015-0009 |
Page generated in 0.0021 seconds